SPDR S&P Biotech ETF
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
17% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 21 (+3) [Q3]
11% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 82
1% more funds holding
Funds holding: 749 [Q2] → 758 (+9) [Q3]
4% more capital invested
Capital invested by funds: $9.75B [Q2] → $10.1B (+$402M) [Q3]
8.52% less ownership
Funds ownership: 138.32% [Q2] → 129.8% (-8.52%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 234 | Existing positions reduced: 269
16% less call options, than puts
Call options by funds: $2.8B | Put options by funds: $3.33B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 4 articles about XBI published over the past 30 days
Positive
Market Watch
1 week ago
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Neutral
Seeking Alpha
3 weeks ago
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with multiple drug candidates.
Positive
MarketBeat
4 weeks ago
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
Positive
Seeking Alpha
1 month ago
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leading the HHS are likely overblown; his confirmation is uncertain, and his focus may impact the food sector more than biotech. The biotech sector appears oversold with little “froth,” especially compared to the overall market, suggesting a buying opportunity for long-term investors.
Positive
Zacks Investment Research
1 month ago
5 Top-Ranked ETFs to Buy on the Dip
Investors can take advantage of beaten-down prices because the second Trump administration is likely to boost stocks.
Negative
Zacks Investment Research
1 month ago
Trump Taps RFK for HHS: Time to Avoid Biotech?
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.
Neutral
CNBC Television
1 month ago
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
Positive
Investors Business Daily
1 month ago
Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?
Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Donald Trump clinched his second presidency. The post Biotech Stocks Edge Higher.
Neutral
Zacks Investment Research
1 month ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.
Charts implemented using Lightweight Charts™